Is ELV a Buy? What to Consider in 2026
Short answer
The bull case for Elevance Health (ELV) rests on Carelon services and pharmacy expansion: Carelon, which includes CarelonRx and risk-based care services, grew operating revenue about 33 percent in 2025 to roughly $71.7 billion, aided by the CareBridge acquisition. Revenue (TTM) is ~$200 billion. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice. Whether ELV is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Elevance Health (formerly Anthem) is a diversified health insurer and healthcare services company that covers roughly 45.6 million medical members as of mid 2025. Its Health Benefits segment sells commercial, Medicare Advantage, Medicaid, and ACA marketplace plans, operating Blue Cross Blue Shield plans across 14 states, while its fast-growing Carelon segment houses pharmacy benefits (CarelonRx) and risk-based care services. Operating revenue reached roughly $197.6 billion in 2025, with Carelon revenue climbing about 33 percent on CarelonRx growth and the CareBridge acquisition. The investment picture is that of a mature, defensive cash machine trading at a low earnings multiple, reflecting market worry about medical cost inflation rather than doubt about the franchise. Management raised full-year 2026 adjusted EPS guidance to at least roughly $26.75 after a Q1 2026 beat, but flagged a higher benefit expense ratio driven by Medicaid cost trend. Investors weigh Elevance's scale, diversification into services, and shareholder returns against a regulated, thin-margin insurance model where a few points of medical loss ratio move earnings materially.
What's the case for buying ELV?
1. Carelon services and pharmacy expansion
Carelon, which includes CarelonRx and risk-based care services, grew operating revenue about 33 percent in 2025 to roughly $71.7 billion, aided by the CareBridge acquisition. This shifts Elevance's mix toward higher-growth, capital-lighter services revenue that is less exposed to pure insurance underwriting swings. Management frames Carelon as a core margin and growth engine alongside traditional insurance.
2. Government programs repricing
Medicare Advantage membership growth and Medicaid rate updates are central to the 2026 story. Elevance has been pressing state partners for Medicaid rates that better reflect the acuity of members retained after post-pandemic redeterminations. If premium yields catch up to medical cost trend, margins in government business can normalize over the coming year.
3. Capital return and low valuation
Elevance generates substantial cash, funding dividends and buybacks, and trades at a trailing P/E around 11 to 12 times, well below the broad market. The company reaffirmed its 2026 earnings and cost targets, and continued EPS growth combined with share repurchases is a key part of how the stock is positioned relative to its modest multiple.
4. Diversification across the insurance book
A spread across commercial (employer and individual), Medicare, Medicaid, and ACA marketplace plans gives Elevance multiple demand pools. Softness in one line, such as Medicaid cost pressure, can be partly offset by strength elsewhere, including a noted shift toward bronze-tier ACA plans. This breadth is the buffer against any single program's cost shock.
What are the risks to ELV?
The dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice. Elevance is heavily exposed to government programs, so Medicaid rate adequacy, Medicare Advantage rate notices, and ACA subsidy policy are all regulatory swing factors outside its control. Integration risk from acquisitions like CareBridge, litigation and audit exposure common to large payers, and the political sensitivity of health insurer profits add further uncertainty. Because insurance margins are thin, a few points of adverse medical loss ratio can move earnings sharply, which is a key reason the stock carries a low multiple.
How is ELV valued? (as of April 2026)
Snapshot for ELV as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$200 billion
- FY2025 operating revenue: ~$197.6 billion
- FY2025 net income: ~$5.7 billion
- FY2026 adjusted EPS guidance: at least ~$26.75
- Market cap: ~$83 billion
- Trailing P/E: ~11.5x
- Medical membership: ~45.6 million
Elevance trades at a low double-digit earnings multiple, reflecting investor caution on medical cost trend rather than doubt about scale. Q1 2026 operating revenue was roughly $49.5 billion with adjusted EPS of about $12.58, and management raised full-year guidance while reaffirming its benefit expense ratio target near 90.2 percent. These figures are approximate and as of April 2026; verify current numbers before acting.
How do you decide if ELV is a buy?
Rather than asking whether ELV is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ELV indirectly through an index or sector ETF before adding more.
For the full picture, see the ELV stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ELV against your real portfolio and see your actual exposure before deciding.
The bottom line on ELV
The bottom line: Elevance Health's story right now is Carelon services and pharmacy expansion, with revenue (ttm) at ~$200 billion. If you believe that narrative continues, the call is about sizing ELV sensibly and checking overlap with what you own; if you doubt it (the risk: the dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around ELV with Walnut
Use Elevance Health as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ELV a good stock to buy right now?
+
The case for Elevance Health right now is Carelon services and pharmacy expansion, with revenue (ttm) at ~$200 billion. If you believe that thesis holds, ELV is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Elevance Health do?
+
Elevance Health (formerly Anthem) is a diversified health insurer and healthcare services company that covers roughly 45.6 million medical members as of mid 2025.
What are the main risks of ELV?
+
The dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice. Elevance is heavily exposed to government programs, so Medicaid rate adequacy, Medicare Advantage rate notices, and ACA subsidy policy are all regulatory swing factors outside its control. Integration risk from acquisitions like CareBridge, litigation and audit exposure common to large payers, and the political sensitivity of health insurer profits add further uncertainty. Because insurance margins are thin, a few points of adverse medical loss ratio can move earnings sharply, which is a key reason the stock carries a low multiple.
What is ELV?
+
ELV is the NYSE ticker for Elevance Health, a large US health insurer and healthcare services company formerly known as Anthem. It operates Blue Cross Blue Shield plans across 14 states and covers roughly 45.6 million medical members.
Why did Anthem change its name to Elevance Health?
+
Anthem rebranded to Elevance Health in 2022 to reflect its broader ambition beyond traditional health insurance, including its Carelon health services and pharmacy businesses. The stock ticker changed from ANTM to ELV as part of that transition.
How does Elevance Health make money?
+
Elevance earns premiums from members across commercial, Medicare Advantage, Medicaid, and ACA marketplace plans in its Health Benefits segment. Its Carelon segment adds revenue from pharmacy benefits (CarelonRx) and risk-based care services, a faster-growing, services-oriented part of the business.
What are Elevance's main business segments?
+
The two core segments are Health Benefits, which sold about $167.1 billion of operating revenue in 2025, and Carelon, which grew about 33 percent to roughly $71.7 billion. Health Benefits is the insurance book, while Carelon houses pharmacy and care services.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ELV; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.